Table 2.

Romiplostim in the treatment of children with chronic immune thrombocytopenia and health-related quality of life

Study	Design	N	Median age (years)	Duration of ITP prior to romiplostim	Median number of treatments	Length of treatment (weeks)	Outcome (KIT scores)
Tarantino et al42	Randomized	42	10	1.9 years	12% other concommitant therapy at baseline	24	No difference in KIT scores – child self, parent proxy, or parent impact. Parent impact scores improved in mixed effect
Mathias et al46	Randomized	42	Mean 9.7 years	Mean 3 years	38% received ≥3 treatments	24	KIT scores – self/proxy and parent impact – greater reduction in parent burden from baseline w/romiplostim (compared with placebo) – P=0.015
Klaassen et al45	Randomized	17	9	2.4 years	94% with prior treatment	12	KIT scores – self/proxy and parent impact – greater reduction in parent burden from baseline w/romiplostim (compared with placebo) – P=0.008

Abbreviations: ITP, immune thrombocytopenia; K IT, kids’ ITP tools.